Supplementary files "Long-term effectiveness and safety of risankizumab for the treatment of plaque psoriasis in a real-life Italian multicenter cohort - IL PSO (ITALIAN LANDSCAPE PSORIASIS)"

Supplementary Figure 1. Mean PASI trend during the study. PASI: Psoriasis Area and Severity Index.
Supplementary Figure 2. Effectiveness of risankizumab according to previous exposure to biological therapies. PASI: Psoriasis Area and Severity Index. * p-value < 0.05; ** p-value ≤ 0.01; *** p-value ≤ 0.001
Supplementary Figure 3. Kaplan-Meier curve of all-cause treatment discontinuation in all patients treated with risankizumab up to 36 months.
Supplementary Table 1. Mean PASI at each time-point according to all analyzed variables. PASI: Psoriasis Area and Severity Index. mPASI: mean PASI; PsA: Psoriatic Arthritis; CMD: Cardio-Metabolic Disease; BMI: Body Mass Index.
Supplementary Table 2. Effectiveness of risankizumab according to the concomitant presence of PsA. PsA: Psoriatic Arthritis
Supplementary Table 3. Effectiveness of risankizumab according to the presence of cardio-metabolic comorbidities and involvement of difficult-to-treat areas. PASI: Psoriasis Area and Severity Index; OR: Odds Ratio; CI: Confidence Interval; CMD: Cardio-Metabolic Disease; NA: Not Applicable (multivariate analysis was not performed for these variables, as the p-value at univariate analysis was ≥ 0.2); NS: Not Significant
Supplementary Table 4. Effectiveness of risankizumab according to BMI classes. BMI: Body Mass Index; OR: Odds Ratio; CI: Confidence Interval; NA: Not Applicable (multivariate analysis was not performed for these variables, as the p-value at univariate analysis was ≥ 0.2); NS: Not Significant. ^ Obese versus normal-weight patients; * Obese versus overweight patients; ° Normal-weight versus overweight patients.